Indications, usage and dosage of lapatinib

Lapatinib is a treatment for advanced hormone-related breast cancer, especially in patients whose disease has progressed or spread despite taking other anticancer drugs. The prerequisite for its application is that the patient's tumor must test positive for a specific protein - human epidermal growth factor receptor 2 (HER2), because the HER2 protein has the property of accelerating the growth of cancer cells.

In terms of treatment plan, for postmenopausal women, lapatinib will be used in combination with a hormonal drug letrozole (Femara) to exert a synergistic therapeutic effect. For patients who are not postmenopausal or who are not suitable for hormone therapy, lapatinib will be used in combination with another anti-cancer drug, capecitabine (Xeloda), to jointly fight the growth and spread of cancer cells. Such combined treatment strategies aim to provide patients with more precise and effective treatment options.

For patients with HER2-positive metastatic breast cancer, when lapatinib is given in combination with capecitabine, the recommended dose is: lapatinib 1,250 mg orally daily on days 1 through 21. This 21-day treatment cycle needs to be used in combination with capecitabine. The dose of capecitabine is 2000 mg/square meter of body surface area/day, taken orally in two doses, with an interval of about 12 hours between the two doses. The administration time of capecitabine is from days 1 to 14. This 21-day treatment cycle will then be repeated.

For patients with hormone receptor-positive, HER2-positive metastatic breast cancer, when lapatinib is combined with letrozole, the recommended dose is: 1,500 mg of lapatinib orally daily from days 1 to 21, and continued use in combination with letrozole, with a dose of 2.5 mg orally once daily.

Please note that the above dosage and medication regimen should be strictly followed as prescribed by the doctor and adjusted according to the patient's specific condition and tolerance. During the treatment process, patients should pay close attention to their physical condition and communicate with their doctor in time if they experience any discomfort or abnormal reactions.

xa0

Reference materials:https://www.drugs.com/mtm/lapatinib.html